SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Oxford Health Plan (OXHP) -- Ignore unavailable to you. Want to Upgrade?


To: men mailman who wrote (1230)3/4/1998 3:04:00 PM
From: DRRISK  Respond to of 2068
 
I think they took the article from Raptor's post. He really called that article, I think he has WSJ insider info. I agree that this article is the last gasp of the negative mongers. The deal I doubt is in trouble but if it tanks it will be because Price or Payson have an alternative which looks better. This is a negotiation now and Payson is rushing to better this deal if he can. It is getting interesting and the pressure to improve upon Bonderman's offer is mounting. It would have been reckless for the CFO (Al Koch) to have responded in the way he did to the writers if he could not back it up.
DrRisk



To: men mailman who wrote (1230)3/4/1998 4:18:00 PM
From: men mailman  Read Replies (1) | Respond to of 2068
 
Just called Dr. Payson's office and mentioned a few ideas to make their packages real attractive. They were willing to hear.

The competition instead of focusing on knocking Oxford better focus on business and improvements.

You understand why I would not publicize these ideas, since I would rather the competition copy Oxford as usual after Oxford intruduces them.

I think the cardio news today is reassuring.

It boggles the mind how 2 (not 1) WSJ staffers write an article with old news. What a sham.

The deal will NOT fall thru. The stock closed 16 7/8 -1/16. However they SHOOK out some small guys of 2 mil shares. (The shorts were probably active buyers).